PHI with Ataxia telangiectasia
How does this condition affect your private health insurance?
Ataxia-telangiectasia (A-T) is a rare, progressive, neurodegenerative, genetic disorder affecting multiple body systems. It's characterized by progressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, increased cancer risk (especially leukemia and lymphoma), and hypersensitivity to ionizing radiation. Symptoms typically appear in early childhood, around ages 1-4, with difficulty walking, poor balance, and slurred speech. The immune system is severely compromised, leading to recurrent infections. Neurological decline continues, often leading to wheelchair dependence by adolescence.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Ongoing from early childhood onset, progressive.
Duration of Illness (Lifetime)
Chronic and lifelong, progressive deterioration.
Cost of Treatment (Initial)
High, involving extensive diagnostic testing, specialist consultations, and early therapeutic interventions.
Cost of Treatment (Lifetime)
Very high, encompassing lifelong multidisciplinary care, management of recurrent infections, cancer surveillance and treatment, physical therapy, assistive devices, and palliative care.
Mortality Rate
High, with a median life expectancy typically in the early to mid-20s due to respiratory failure, severe infections, or cancer.
Risk of Secondary Damages
Very high; includes progressive neurological decline, severe immunodeficiency leading to recurrent infections, significantly increased risk of various cancers (lymphoma, leukemia), respiratory complications, endocrine dysfunction, and psychological impact.
Probability of Full Recovery
Virtually zero; it is a progressive neurodegenerative disorder with no known cure.
Underlying Disease Risk
High; severe immunodeficiency (affecting ~70% of patients), significantly increased risk of various cancers (especially leukemia and lymphoma), and endocrine disorders like insulin-resistant diabetes.